[HTML][HTML] Del-1, an endogenous inhibitor of TGF-β activation, attenuates fibrosis

DY Kim, SH Lee, Y Fu, F Jing, WY Kim… - Frontiers in …, 2020 - frontiersin.org
DY Kim, SH Lee, Y Fu, F Jing, WY Kim, SB Hong, JA Song, H Choe, HJ Ryu, M Kim, D Lim…
Frontiers in immunology, 2020frontiersin.org
Uncontrolled activation of transforming growth factor (TGF)-β results in a wide range of
pathologic conditions. Therapeutic interventions to regulate TGF-β signaling during fibrosis
have been developed but the effectiveness is still limited. Here, we show that developmental
endothelial locus-1 (Del-1) ameliorates fibrosis in mice by inhibiting αv integrin-mediated
activation of TGF-β. Del-1 bound to αvβ6 integrin, an important activator of TGF-β, and
inhibited the binding of αvβ6 integrin to the latency-associated peptide (LAP), thereby …
Uncontrolled activation of transforming growth factor (TGF)-β results in a wide range of pathologic conditions. Therapeutic interventions to regulate TGF-β signaling during fibrosis have been developed but the effectiveness is still limited. Here, we show that developmental endothelial locus-1 (Del-1) ameliorates fibrosis in mice by inhibiting αv integrin-mediated activation of TGF-β. Del-1 bound to αvβ6 integrin, an important activator of TGF-β, and inhibited the binding of αvβ6 integrin to the latency-associated peptide (LAP), thereby suppressing αv integrin-mediated activation of TGF-β. Lack of Del-1 increased colocalization of αv integrin and LAP in the lungs, which was reversed by Del-1 supplementation. The crucial role of Del-1 in regulating TGF-β activity was recapitulated in a mouse model of fibrosis using an adenovirus expressing inactive TGF-β1. Del-1 supplementation improved the pathological characteristics of the mice and reduced mortality. Thus, we propose that Del-1 is a negative regulator of TGF-β activation and a potential anti-fibrotic factor.
Frontiers